LGVN Longeveron

Longeveron to Present at the Annual Dawson James Small Cap Growth Conference

Longeveron to Present at the Annual Dawson James Small Cap Growth Conference

MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that Chris Min, M.D., Ph.D., Interim Chief Executive Officer, and Chief Medical Officer at Longeveron, will present at the upcoming Dawson James Small Cap Growth Conference taking place in Jupiter, Florida from October 11-12, 2022.

Longeveron’s presentation will take place on Wednesday, October 12, 2022 from 4:30 – 4:55 p.m. ET. A live webcast of the presentation can be accessed by visiting “Events & Presentations” in the Investors section of Longeveron’s website at . A replay of the webcast will be available shortly following the conference.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has a multi-modal mechanism of action that is pro-vascular, pro-regenerative, and anti-inflammatory, promoting tissue repair and healing with broad potential applications across a spectrum of disease areas. Longeveron is advancing Lomecel-B™ through clinical trials in three indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s Disease, and Aging Frailty. Additional information about the Company is available at .

Investor Contact:

Elsie Yau

Stern IR, Inc.

212-698-8700

  





EN
05/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Longeveron

 PRESS RELEASE

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportuni...

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference MIAMI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will participate in the 4th Annual ROTH Healthcare Opportunities Conference. Longeveron management will host one-on-one meetings with investors at the conference to be held October 9, 2025 in New York. About Longeveron Inc. Longeveron is a clinical stage biotechnology company dev...

 PRESS RELEASE

George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, ...

George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that George Paletta, Jr., MD, MBA, has been elected to the Longeveron Board of Directors. Dr. Paletta is a nationally and internationally recognized orthopedic surgeon and the head team doctor for the St. Louis Cardinals. Dr. Paletta is a deve...

 PRESS RELEASE

Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene...

Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa Exploring potential partnerships and strategic opportunities for the Company’s stem cell therapy program in Alzheimer’s diseaseAlzheimer’s disease development program with positive data in successful Phase 1 and Phase 2a clinical trialsClear regulatory pathway following positive Type B meeting with U.S. FDAFDA has granted laromestrocel both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s disease MIAMI, Sept. 22, 2025 (GLOBE ...

 PRESS RELEASE

Longeveron® Announces Key Leadership Updates

Longeveron® Announces Key Leadership Updates Than Powell, Chief Business Officer and head of business development, appointed Interim CEODr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of DirectorsWa’el Hashad to step down as CEO and Board memberNational search to occur for permanent CEO MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced key leadership u...

 PRESS RELEASE

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Inves...

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 in New York City. Details for the Company’s presentation:    Date:Monday, September 8, 2025 Time:4:00 – 4:30 p.m. ET    The webcast for this conf...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch